| [1] | 
													
														CHEN Yaozhe, ZHAN Yunli, SONG Xingdong, ZHU Manyu, OU Xuemei, LI Chuyun. 
														
															48 Cases of Hematological Adverse Reactions Associated with Piperacillin Sodium and Tazobactam Sodium
														[J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 794-798.
													 | 
												
																																																																																
													| [2] | 
													
														XIE Ziyue, WANG Chengxiang, HU Yanpeng, LI Lei, CUI Herong. 
														
															Clinical Medications and Safety Analysis of Traditional Chinese Medicine for Post-Infection Cough
														[J]. Chinese Journal of Pharmacovigilance, 2025, 22(5): 507-512.
													 | 
												
																																																																																
													| [3] | 
													
														JIN Shaoming, NING Xiao. 
														
															Uncertainty Evaluation for Determination of Ambroxol in Rat Plasma by UPLC-MS/MS Method
														[J]. Chinese Journal of Pharmacovigilance, 2025, 22(4): 381-385.
													 | 
												
																																																																																
													| [4] | 
													
														ZHANG Yunhui, CHEN Haoyun, ZHONG Luhua, FANG Caifu, HUANG Huanjun, GUO Chenchen, DONG Xinyi, SHI Feng, LIANG Weiting. 
														
															159 Cases of Adverse Reactions to Immune Checkpoint Inhibitors
														[J]. Chinese Journal of Pharmacovigilance, 2025, 22(4): 442-446.
													 | 
												
																																																																																
													| [5] | 
													
														WANG Han, WANG Cunxuan, LYU Xuehaiyue, ZHANG Lining, SUO Yusi, GU Zhi'en, WANG Ping, JIN Xuejing. 
														
															Chinese Patent Medicines for Preventing Myelosuppression in Adjuvant Treatment of Malignant Tumors: a Systematic Review and Network Meta-Analysis
														[J]. Chinese Journal of Pharmacovigilance, 2025, 22(2): 169-176.
													 | 
												
																																																																																
													| [6] | 
													
														YANG Shengxi, XU Juntong, TU Wenlian. 
														
															Research Progress in the Treatment of Advanced Non-Small Cell Lung Cancer with Aumonertinib
														[J]. Chinese Journal of Pharmacovigilance, 2025, 22(2): 235-240.
													 | 
												
																																																																																
													| [7] | 
													
														LU Zhenkai, YANG Dingquan, XIE Zhennian, WANG Lianxin, LI Yuanyuan, WANG Zhifei, CUI Xin, XIE Yanming. 
														
															Interpretation and insights from the “Guidelines for Pharmacovigilance of Topical Traditional Chinese Medicines in Clinical Applications”
														[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1029-1033.
													 | 
												
																																																																																
													| [8] | 
													
														MENG kangkang, XIA Yukun. 
														
															Risks to safety of Ondansetron preparations
														[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1034-1038.
													 | 
												
																																																																																
													| [9] | 
													
														LIN Lu, ZHAN Luchuan, LIU Xiaoqi, LIU Ju'e, WANG Laiyou, ZENG Ying, LAI Weihua. 
														
															Establish triggers for active monitoring of digoxin adverse events based on the China hospital pharmacovigilance system
														[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1039-1043.
													 | 
												
																																																																																
													| [10] | 
													
														YAN Yan, LIU Naiyi, QIAO Ling, ZHANG Yi, YANG Chen. 
														
															One case of fulminant type 1 diabetes mellitus induced by allopurinol tablets hypersensitivity syndrome
														[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1068-1070.
													 | 
												
																																																																																
													| [11] | 
													
														LU Jing, YU Shanshan, TONG Fei, LIN Zhuohui, SONG Luyao. 
														
															One case of severe constipation caused by dapagliflozin
														[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1071-1074.
													 | 
												
																																																																																
													| [12] | 
													
														LI Fang, LONG Xiuying, BAI Na, WEI Jingxia. 
														
															One case of severe systemic rash caused by atorvastatin calcium tablets
														[J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 939-942.
													 | 
												
																																																																																
													| [13] | 
													
														LIU Yan, AN Jing, JIAO Yongzhuo, LIANG Xuefeng, ZHANG Xiaoshu. 
														
															Simple febrile seizures within 30 days of vaccination with the measles, mumps and rubella combined attenuated live vaccine in U-12 children in the real world
														[J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 805-810.
													 | 
												
																																																																																
													| [14] | 
													
														ZHAO Xuan, ZHENG Tingting, LI Xuemei, MAO Lu, GUO Jing, ZHANG Wei. 
														
															Adverse reaction reports of vancomycin in a hospital
														[J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 811-815.
													 | 
												
																																																																																
													| [15] | 
													
														SHAO Bo, XU Lili, ZHU Lan, LIU Shuo, WAN Hao, HUANG Guangrui. 
														
															Risks of liver injury caused by Shiduqing preparations
														[J]. Chinese Journal of Pharmacovigilance, 2024, 21(6): 666-670.
													 |